Okamoto launches VivaGel® condom in Japan
Starpharma today announced that the VivaGel® condom has been launched in Japan under Okamoto’s leading and highly successful Zero Zero Three (003) brand. This is the first condom with antiviral coating in Japan and will also carry Starpharma’s VivaGel® brand.
Starpharma signs second oncology agreement with AstraZeneca
|
Online investor news outlet Finance News Network reported on Starpharma’s second oncology agreement with global pharmaceutical giant AstraZeneca, noting that this is for the development of a DEP® version of an undisclosed and existing market oncology drug. |
Read the full article here (requires sign in).
Starpharma signs second oncology agreement with AstraZeneca
Starpharma today announced a Development and Option Agreement with AstraZeneca (LON: AZN) to progress the development of a Dendrimer Enhanced Product (DEP®) version of an undisclosed AstraZeneca major marketed oncology medicine. This is the second DEP® commercial agreement Starpharma has signed with AstraZeneca, the first agreement being a multiproduct licence which covers novel oncology drug candidates such as AZD0466 (a Bcl2/xL inhibitor).
Starpharma presents at UBS Healthcare Conference
Starpharma has been invited to present today at the UBS Australian Emerging Companies Conference - Healthcare and Biotech – in Sydney. The UBS Healthcare Conference provides Starpharma with an opportunity to present to approximately 100 institutional investors.
DEP® irinotecan combination outperforms in refractory human colon cancer model
Starpharma today announced that its patented nanoparticle formulation, DEP® irinotecan, showed significant efficacy and safety benefits over leading colorectal cancer drugs irinotecan (Camptosar®) and cetuximab (Erbitux®), in the irinotecan-refractory HT-29 human colon cancer model.
These impressive results were despite the fact that these standard colorectal cancer (CRC) treatments, Camptosar® and/or Erbitux®, showed limited activity in this preclinical model.
Regulatory progress for VivaGel BV in the US
Starpharma has received formal feedback from the recent meeting held with the US FDA in relation to the approval for two related bacterial vaginosis (BV) indications - BV treatment and the prevention of recurrent BV in the United States.
Starpharma to present at US Drug Delivery Conference
Starpharma today announced that it will be presenting its DEP® platform at the 2nd Annual Drug Delivery West conference in San Francisco on 6-7 May 2019 (US time).
Starpharma presents at Macquarie Australia Conference
Melbourne, Australia; 1 May 2019: Starpharma (ASX: SPL, OTCQX: SPHRY) has been invited to present today at the Macquarie Australia Conference in Sydney. The Macquarie Australia Conference is a leading investment event in Australia and attracts more than 800 investors from around the world, including Asia, Europe and North America.
Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2019.
Starpharma on Channel Nine News (April 22, 2019)
|
Channel Nine News reported on the launch of VivaGel® BV (Fleurstat BVgel) in Australia and noted it was a world first, novel and non-antibiotic treatment developed in Australia. The report noted BV affects 12 percent of Australian women and if left untreated could lead to infertility, early delivery or miscarriage. |
Read the TV news segment here.